Aquestive Therapeutics (AQST) opened Q1 2026 with revenue of US$14.4 million and a reported loss of US$8.1 million, equal to a basic EPS loss of US$0.07. The trailing twelve months show revenue of US$50.3 million and a net loss of US$68.9 million or EPS of US$0.61. Over recent quarters the company has reported revenue rising from US$8.7 million in Q1 2025 to US$14.4 million in Q1 2026, with quarterly EPS losses ranging from US$0.24 to US$0.26 through 2025 before narrowing to US$0.07 in the latest period. For investors, a central question is whether these revenue gains can eventually support more sustainable margins.

See our full analysis for Aquestive Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings release compares with the most common narratives around Aquestive Therapeutics and where those views might need updating.

Revenue climbs while losses stay sizeable

• Quarterly revenue rose from US$8.7 million in Q1 2025 to US$14.4 million in Q1 2026, while net loss for Q1 2026 was US$8.1 million and trailing twelve month revenue and net loss stood at US$50.3 million and US$68.9 million respectively.
• Consensus narrative highlights Anaphylm and related oral film products as key drivers for future revenue growth, and this revenue track record provides some support but also shows that growth so far has not yet translated into profitability.
  • Over the last five reported quarters, revenue moved from US$8.7 million to US$14.4 million, yet trailing twelve month losses widened from US$44.1 million in Q4 2024 to US$68.9 million in Q1 2026, so higher sales have come with ongoing heavy spending.
  • Analysts expect roughly 30.6% annual revenue growth, but with the company still reporting a loss of US$8.1 million in the latest quarter, the story the numbers tell today is that growth is being bought with continued negative earnings.

Loss per share narrows but profits still distant

• Basic EPS loss moved from US$0.24 in Q1 2025 to US$0.07 in Q1 2026, while on a trailing twelve month basis EPS loss sits at US$0.61 compared with US$0.51 at Q4 2024.
• Supporters of the bullish view point to expectations that margins could eventually improve, yet the current EPS pattern shows only gradual loss reduction over five years, with no quarter in this dataset showing positive earnings.
  • Over the past five years, losses have reportedly been reduced at about 1.4% per year, which is a slow pace compared with the much faster revenue growth that bullish investors focus on.
  • Even after the recent quarterly EPS loss narrowing to US$0.07, the trailing twelve month EPS loss of US$0.61 and net loss of US$68.9 million mean the company is still far from the positive earnings levels that bullish forecasts discuss.

Bulls arguing that accelerating revenue will eventually overpower these losses are leaning on projections that go well beyond what Q1 numbers currently show, so if you want to see how that optimistic case is built out, it is worth reviewing the 🐂 Aquestive Therapeutics Bull Case

Premium P/S multiple with real balance sheet pressure

• The stock trades at a P/S of 11.8x compared with 5.4x for the US Pharmaceuticals industry and 1x for peers, while shareholders have faced dilution over the past year and the company reports negative shareholders’ equity.
• Bears argue that paying this kind of premium for a company that is unprofitable and expected to stay that way for at least three years sets a high bar, and the current financials give their concerns tangible backing.
  • Trailing twelve month revenue of US$50.3 million and a net loss of US$68.9 million mean the market is valuing each dollar of sales at more than double the industry average multiple even though none of that revenue currently drops to the bottom line.
  • Reported shareholder dilution and negative equity also align with bearish worries about ongoing funding needs, because raising capital to cover losses typically adds pressure to existing holders when the stock is already trading on an elevated P/S.

Skeptics who are focused on that rich P/S, ongoing losses, and negative equity can dig into how the cautious case lines up against these Q1 figures by checking out the 🐻 Aquestive Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aquestive Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bull and bear angles, the real question is where you land. Take a closer look at the underlying data and risks, then weigh them against the potential rewards by reviewing the 1 key reward and 4 important warning signs

See What Else Is Out There

Aquestive Therapeutics combines sizeable ongoing losses and negative equity with a premium P/S multiple, which places considerable pressure on future execution to justify the valuation.

If that combination of funding pressure and elevated pricing feels uncomfortable, you may wish to focus on companies with sturdier finances. You can start by looking at the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.